

# **Full National Burden of Disease Study in Switzerland (BoD-CH): Opportunities and Challenges**

-----

## **Case Study on Diabetes mellitus: Disease Burden and Patterns of Care in Switzerland**

*Report of a Key Stakeholder Workshop  
on 26 August 2019 at Swiss TPH in Basel  
co-organised by*

Swiss Tropical and Public Health Institute (Swiss TPH)

Scuola Universitaria Professionale della Svizzera Italiana  
(SUPSI)

Università della Svizzera Italiana (USI)

Swiss Health Observatory (OBSAN)

*With financial support of*

Swiss School of Public Health (SSPH+)  
through a seed money contribution to  
„Foster Interuniversity Initiatives and Collaborations“



## Contacts

**Dr. Thomas Fürst**

Senior Scientific Collaborator  
Unit Chronic Disease Epidemiology  
Department Epidemiology and  
Public Health  
Swiss TPH ([www.swisstph.ch](http://www.swisstph.ch))  
Socinstrasse 57  
P.O. Box  
4002 Basel, Schweiz

[thomas.fuerst@swisstph.ch](mailto:thomas.fuerst@swisstph.ch)

T: +41 61 284 87 65 (direct)

**Dr. Monika Diebold**

Head of Swiss Health Observatory  
Swiss Health Observatory (OBSAN) ([www.obsan.admin.ch](http://www.obsan.admin.ch))  
Espace de l'Europe 10  
2010 Neuchâtel, Suisse

[monika.diebold@bfs.admin.ch](mailto:monika.diebold@bfs.admin.ch)

T: +41 58 463 65 58 (direct)

**Prof. Dr. Nicole Probst-Hensch**

Head of Unit & Department  
Unit Chronic Disease Epidemiology  
Department Epidemiology and  
Public Health  
Swiss TPH ([www.swisstph.ch](http://www.swisstph.ch))  
Socinstrasse 57  
P.O. Box  
4002 Basel, Schweiz

[nicole.probst@swisstph.ch](mailto:nicole.probst@swisstph.ch)

M: +41 79 280 34 14

T: +41 61 284 83 78 (direct)

Administration: Nora Bauer Ott

[nora.bauer@swisstph.ch](mailto:nora.bauer@swisstph.ch)

T: +41 61 284 83 88 (direct)

**Prof. Dr. Carlo de Pietro**

Professor of Healthservices Management and Policy  
Dipartimento economia aziendale, sanità e sociale  
SUPSI ([www.supsi.ch](http://www.supsi.ch))  
Piazzetta 209  
Via Violino  
6928 Manno, Svizzera

[carlo.depietro@supsi.ch](mailto:carlo.depietro@supsi.ch)

T: +41 58 666 64 62 (direct)

**Dr. Carlos Quinto**

Senior Scientific Collaborator  
Unit Chronic Disease Epidemiology  
Department Epidemiology and  
Public Health  
Swiss TPH ([www.swisstph.ch](http://www.swisstph.ch))  
Socinstrasse 57  
P.O. Box  
4002 Basel, Schweiz

[carlos.quinto@swisstph.ch](mailto:carlos.quinto@swisstph.ch)

T: +41 61 284 83 89 (direct)

# Content

<b>Contacts</b>	<b>2</b>
<b>Content</b>	<b>3</b>
<b>Background</b>	<b>4</b>
<b>Explicit and implicit goals and objectives</b>	<b>5</b>
<b>Outcomes</b>	<b>6</b>
<b>Potential next steps</b>	<b>9</b>
<b>References</b>	<b>10</b>
<b>Appendix 1: Workshop agenda</b>	<b>11</b>
<b>Appendix 2: Workshop participants</b>	<b>12</b>
<b>Appendix 3: Slides presented during workshop</b>	<b>16</b>

## Background

Over the past two decades, the Global Burden of Disease (GBD) study has evolved into the most comprehensive worldwide descriptive epidemiological study.<sup>1</sup> The GBD study results are highly cited and core staff members are considered to be among “the world’s most influential scientific minds”.<sup>2</sup> Currently, the GBD consortium describes age- and sex-specific mortality and morbidity due to 359 major diseases and injuries at global, regional, national, and for selected countries also at subnational level, for the years 1990-2017.<sup>1</sup> Moreover, the use of a common methodology and summary measure of population health – the disability-adjusted life years (DALYs) – make all burden estimates comparable across all these dimensions. For instance, it allows for national age- and sex-specific health loss comparisons across different conditions by combining information on mortality and morbidity, which is highly relevant as “death does not tell the full story”.<sup>3</sup> Developing and developed countries increasingly realize the value of such age- and sex-specific national and subnational burden of disease studies to inform their health policies (for instance, see <sup>4,5</sup> for England or <sup>6</sup> for Norway). Also, the standardized methodology and measure (i.e. DALYs) enables cross-country comparisons, which can provide useful hints about (in)efficiencies in a national health system.<sup>4-6</sup>

Discussions with national and international colleagues indicate that the more “top-down” approach from the GBD collaboration can powerfully complement more localised and cause-specific “bottom-up” approaches in assessing national population health, health policy, and data gaps. In the highly fragmented Swiss public health landscape, pragmatic national burden of disease studies constitute an interesting opportunity to combine various specialties and geographies and gain a more comprehensive and nationally and internationally comparable overview over the health of the population in Switzerland. A solid analysis of the health of the Swiss population may also help to spark broader based and better informed discussions about health system choices and priorities in times of constantly rising health insurance bills. In fact, the aforementioned English national burden of disease studies (see reference <sup>4,5</sup> above) received tremendous media attention (media coverage survey can be shared if deemed relevant) and consequently, burden of disease studies seem to provide “a new packaging for communicating old and new public health findings to the general public” (personal comment Prof. John Newton, Director of Health Improvement, Public Health England).

Of note, colleagues involved in (sub-)national burden of disease studies in other countries reported substantial inaccuracies in international burden assessments such as the GBD study when compared with national data. One of the main reasons for these inaccuracies are differences in disease progression due to differences in the (sub-)national healthcare systems (personal communication Dr. Ian Grant, Principal Researcher, Scottish Burden of Disease, Scottish Health Observatory). The provision or lack of treatment in healthcare services influence disease progression, thereby impact on population health, and should thus be reflected in burden assessments. However, international burden assessments often lack the expertise and/or resources to pay attention to the various (sub-)national patterns of care and often rely on models informed by national and international proxies and explanatory variables.

A well-structured description of patterns of healthcare services is relevant per se, of course, and beyond its importance for burden assessments. Again, in the highly fragmented Swiss healthcare system, a multitude of localised and specialised initiatives and organisations evolved over time to address various healthcare needs of the population. Often, a clear overview of such healthcare services is lacking. This lack of an overview impedes the well-informed decision making of patients, healthcare providers, politicians and other partners and stakeholders.

This report is from a workshop that focused on the disease burden of and patterns of care for diabetes mellitus in Switzerland. Diabetes mellitus was selected for the case study as it is a chronic, non-communicable disease, which constitutes a major public health problem in Switzerland and requires a complex, specialised and well-coordinated care. Furthermore, diabetes mellitus is a good example of a disease with a limited and scattered data base regarding the national descriptive epidemiology and patterns of care. The rate of under-diagnosis is likely to be substantial. As diabetes can lead to a multitude of sequelae, the disability that can be etiologically linked with diabetes is important, but difficult to evaluate. Also, most patients do not die from diabetes directly but rather its longer-term sequelae, and hence, cause of death statistics may be inaccurate. Last but not least, the subdivision of the numbers into cases of type 1 and type 2 diabetes is unknown.

### Explicit and implicit goals and objectives

In agreement with the managers of SSPH+, the initial proposal for exploring opportunities and challenges that may arise from a full (i.e. including the most important causes of mortality and morbidity) national burden of disease study by visiting and discussing the idea with a few selected key persons was revised. In order to be more concrete and profit from the synergies with a mandate from the Swiss Health Observatory (OBSAN), it was decided to focus on diabetes mellitus instead of a full national burden of disease study and to organize a diabetes stakeholder workshop with the following explicit and implicit goals:

1. Explicit goal of the workshop: Presentation of the project and its current state on the burden and patterns of care for diabetes mellitus in Switzerland.
2. Explicit goal of the workshop: Start a stakeholder dialogue and discussions with potential partners in the fields of diabetes, burden and healthcare research in Switzerland.
3. Implicit goal in the workshop: Explore opportunities and challenges that arise from burden of disease assessments in Switzerland.

These goals were broken down into the following, more specific and explicitly objectives for the workshop:

- i. Feedback on and further completion of the current database regarding (a) relevant stakeholders, (b) relevant health care providers, (c) relevant guidelines, and (d) sources of quantitative data to estimate disease burden.
- ii. Development of applicable/operational characteristics and criteria for integrated diabetes care services & utility and feasibility of identifying typical patient-centered care pathways.
- iii. Start developing a list of integrated diabetes care services and providers.
- iv. Input on potential approaches to identify additional integrated diabetes care services and providers.
- v. Input for a broader stakeholder consultation.
- vi. Discussion on next steps/way forward on the diabetes disease burden and patterns of care assessment in Switzerland, also with an eye towards the identification of potential key parameters for a potential diabetes surveillance program in Switzerland.

The main language of the workshop was English, but inputs in German, French and Italian were also welcomed and – if need be – translated in a pragmatic way by other workshop participants.

The workshop agenda is provided in Appendix 1 of this report.

## Outcomes

After a first stakeholder mapping in the first half of 2019, 86 persons/organizations were invited to participate in the workshop in total. In the end, 24 persons attended the workshop and only from 9 contacts we received no reaction at all. Many of those who could not attend mentioned conflicting dates and appointments as reason. However, they usually emphasized their genuine interest in the topics, provided additional useful information and inputs via email and telephone, wanted to be kept informed and also flagged their interest in future involvement. Those 24 persons who could participate in the workshop came from all major language regions of Switzerland (Ticino, Romandie and Deutschschweiz) and had diverse but highly relevant backgrounds, expertise and affiliations/mandates (see Appendix 2 for a list and photo of all workshop participants). In order to better understand the workshop participants' motivation and also to better target potential future work, a quick written survey was conducted at the very beginning of the workshop. This survey revealed that most participants were mainly interested in the patterns of diabetes care and to a lower degree in diabetes burden assessment in Switzerland (Table 1).

**Table 1: Quick written survey among workshop participants: „How important were the following topics in your decision to participate in the workshop?“**

	Very important	Important	Less important	No answer	Total
"Disease Burden"	6 (25%)	12 (50%)	2 (8%)	4 (17%)	24 (100%)
"Patterns of Care"	17 (71%)	3 (13%)	0 (0%)	4 (17%)	24 (100%)

The workshop was formally opened with a short welcome note from Prof. Juerg Utzinger (Director Swiss TPH) and Prof. Nicole Probst-Hensch (Head of Department of Epidemiology and Public Health at Swiss TPH and Principal Investigator of the Case Study on the Diabetes Mellitus Disease Burden and Patterns of Care in Switzerland). After a quick round of introductions of all participants, Dr. Thomas Fürst (Coordinator of the Project) gave an input presentation on the OBSAN case study mandate on the disease burden and patterns of care of diabetes mellitus in Switzerland. Besides highlighting the current ideas and state of the work, the presentation also provided a short introduction in burden of disease assessments and the calculation of their main metric, the so-called disability-adjusted life years (DALYs) (see Appendix 3, Slides 1-39). The immediately following discussions demonstrated again that many research and applied healthcare projects have been completed over the past years or are currently ongoing. However, all these efforts focused on some specific aspects of the disease and/or covered only a rather limited/specific part of the patients and/or the Swiss population overall. Also, most input from the workshop participants referred to healthcare research and not so much to descriptive epidemiology, which may come as no surprise given the workshop participants' main interests as illustrated in Table 1. Some better or less known examples of completed or currently ongoing research and applied healthcare projects that were mentioned:

- Swiss Diabetes Registry (SwissDiab): Prospective cohort study aiming at including and collecting data of virtually all patients regularly seen and treated at the three study centres (Inselspital Bern, Kantonsspital St. Gallen, Universitätsspital Zürich; ≈ 500 patients per centre), irrespective of type, duration of diabetes or treatment – insights into disease management and course of disease – only patients seen and consenting in the three hospitals.<sup>7</sup>
- Family medicine International Classification of Primary Care (ICPC) Research using Electronic medical records (FIRE project): Research project lead by the Institut für Hausarztmedizin der Universität Zürich (IHAMZ) with the goal to build up a research database containing the electronic records of participating GP practices, following the ICPC classification – insights into underdiagnosis, differentiation between type 1 and 2, disease management and course of disease – only patients seen in participating GP practices.<sup>8</sup>

- Siscare-DT2: Research project lead by Sispha AG, which belongs to the Berufsgenossenschaft der Schweizer Apotheker (Ofac), with the aim to improve treatment adherence of people with diabetes mellitus type 2 – insights into disease management and particularly treatment adherence of people with diabetes mellitus type 2 – thus far, only a comparatively small group of people with diabetes mellitus type 2.<sup>9</sup>
- Health Behaviour in School-Aged Children in Switzerland (HBSC Switzerland): A World Health Organization (WHO) collaborative cross-national study, in Switzerland carried out by Sucht Schweiz, with the aim to assess health behaviour and lifestyles in 11 and 15 years old every four years, based on nationally representative samples – potentially relevant insights into risk factors and prevalence – exact data available still needs verification and only available in 11 and 15 years old, but as a nationally representative sample.<sup>10</sup>

It was also highlighted that a population-based, diabetes-specific screening or surveillance program currently is neither in place nor planned in Switzerland. However, there are some diabetes risk assessment tests, which can be used by patients as well as healthcare professionals. Furthermore, it was mentioned that in a quite successful project in the canton Vaud, pharmacies were encouraged to make also initial diabetes diagnosis as part of a more comprehensive screening of non-communicable diseases (NCDs). Nevertheless, it was emphasized that the age group of the ca. 18-45 year old people may represent a particular challenge in terms of diabetes underdiagnosis and patient loss as they are fully self-responsible and may not yet suffer from any severe and/or specific signs and symptoms. Despite this fact, the colleagues from Ticino reported that they screened approximately 1,200 people in a survey in their canton and did not detect a single new diabetes case that had not been diagnosed previously. In contrast, the optometrist/eye health specialists from Nordwestschweiz provided anecdotal evidence of patients that they see in the hospital with some ophthalmological complaints, which are then referred to a diabetes test and confirmed only then as diabetes patients. These two statements nicely highlight the substantial regional/cantonal variation that may exist in terms of healthcare and underdiagnosis within Switzerland and which one should also keep in mind when reflecting on the descriptive epidemiology and burden of diabetes. Particularly during the discussions on potentially available quantitative data on the descriptive epidemiology and from healthcare research in Switzerland, it was repeatedly confirmed that these data are usually published and should be retrievable by means of a systematic literature review, mainly focusing on PubMed.<sup>11</sup>

Regarding the diabetes guidelines in Switzerland, it was literally mentioned that „it is a jungle“ by the workshop participants. There seem to be various players, which adopt or adapt existing and sometimes also develop their own guidelines. However, when reviewing the websites of the Swiss Medical Association (FMH),<sup>12</sup> the Schweizerische Gesellschaft für Endokrinologie und Diabetologie (SGED),<sup>13</sup> the Programme Cantonal Diabète Vaud<sup>14</sup> and QualiCCare,<sup>15</sup> probably most relevant Swiss guidelines would be covered. From the GPs, it was also criticized that the guidelines are not always very useful as they could frequently not adhere to them because of the often very individual and complex patient situation. As one response to this situation, a „Recommendation pour la Pratique Clinique“ (RPC) for multimorbid patients has been developed by the Programme Cantonal Diabète Vaud<sup>16</sup> and is currently being adapted and tested in two pilot studies in different language regions also in collaboration with QualiCCare.<sup>17</sup> In general, for diabetes patients as well as multimorbid patients suffering from various NCDs, the coordination of care, the compliance, clear patient pathways and the patients' (health) literacy is difficult but critical. Improvements in IT tools that facilitate information sharing and the development of appropriate financing and accounting structures were identified as additional essential factors to better coordinated and potentially even integrated care.

In conclusion, and instead of further working through the advanced versions of a quantitative data database, a guidelines database and a stakeholder database in detail (see Appendix 3, Slides 40-50), it was agreed that these databases will be shared with the workshop participants and they can then further comment and provide input via email.

After a tea break, the focus was more specifically on integrated diabetes care. This second part of the workshop started again with an input presentation by Dr. Thomas Fürst (see Appendix 3, Slides 51-58) and was then co-moderated by Prof. Carlo de Pietro and Dr. Thomas Fürst. It was pointed out that integrated

diabetes care is desirable, but that currently and generally no consensus and/or definition of integrated care exists. Hence, the questions arise what integrated diabetes care means, what would be relevant and operationalizable definitions and criteria for integrated diabetes care, and how thus defined and existing integrated diabetes care initiatives could be captured/identified. The criteria of the first Swiss Survey on Integrated Care (SSIC) were confirmed as a promising potential starting point.<sup>18,19</sup> The SSIC was not condition-specific and used the following inclusion criteria to define integrated care initiatives:

- Formalization: formal written agreement between organizations/institutions.
- Integration at healthcare services level: at least two healthcare services from different levels (e.g. physician-led primary care, non-physician-led primary care, specialised medial outpatient service, home care, community services, etc.).
- Integration at healthcare professionals level: at least two healthcare professionals from different levels (e.g. specialist physician, GP, general nurse, specialist nurse, FaGE (=assistant(e) en soins et santé)/MPA (=assistant(e) médicales), nutritionist, pharmacist, optometrist, physiotherapist, etc.).
- Currently ongoing.

These criteria could be further tailored to the specificities of diabetes care and thereby the precision of the definition and criteria for integrated diabetes care further increased. As an additional critical aspect of integrated diabetes care, the exchange of information and medical data between the different providers was emphasised. However, it was pointed out that a lot of smaller diabetes care networks may exist and hence, there may be some hundred different integrated diabetes care initiatives in Switzerland.

In a short reaction and summary, Dr. Carlos Quinto stated that the work on the descriptive epidemiology and patterns of care for diabetes in Switzerland is of great interest also for the FMH, of course. He also expressed the FMH's willingness to participate and support future efforts. Furthermore, he stressed the substantial heterogeneity that characterises the course and care of diabetes and deduced two key aspects from that: First, the will to work together across professional and institutional boundaries will be essential to further carve out the descriptive epidemiology and patterns of care for diabetes in Switzerland. Second, one has to be careful about the complexities of diabetes and break it down into meaningful (research) questions and projects. Dr. Monika Diebold agreed with these statements, also confirmed the importance of the discussed topics for OBSAN, thanked everybody for all their efforts and expressed her hope to jointly move on. Finally, Prof. Nicole Probst-Hensch concurred with the two previous speakers and officially closed the workshop.



## Potential next steps

- The whole materials and information has been digested and summarized in this short meeting report. A near-final version of the meeting report will be shared with all workshop participants for further input/revisions. The final version of the meeting report will be shared again with all workshop participants.
- Together with the near-final version of the meeting report, the advanced versions of the quantitative data database, the guidelines database and the stakeholder database will be shared with the workshop participants so that they can further comment and provide input.
- Since the workshop, various participants already shared further material, information and insights with the organizers (e.g. additional advice, contacts and references, reports and publications, insights about criteria and labels of good diabetes care, etc.)
- A systematic review will be conducted to summarize the available quantitative data on prevalence, incidence, under-diagnosis, mortality, and differentiation between type 1 and type 2 diabetes (whenever available age- and sex-specific). Together with the records in the already established quantitative data database, this will enable us to provide clear, evidence-based answers on the following diabetes-specific questions:
  - What do we know and what not about the epidemiologic key parameters in Switzerland?
  - What are all the relevant quantitative data sources?
  - What are limitations of the existing data/data sources?
- All diabetes-specific guidelines for Switzerland in the guidelines database will be reviewed and this will enable us to provide clear, evidence-based answers on the following questions:
  - For which aspects do guidelines exist?
  - Based on this guidelines review, which core set of ca. 10-20 aspects/indicators could potentially serve as a core set in a population-based diabetes surveillance in Switzerland?
  - What diabetes surveillance exists in other countries (particularly Germany, France, United Kingdom) and what core indicators do they use?
- All above-mentioned steps will serve as a basis for discussion regarding an improved diabetes surveillance in Switzerland.

## References

1. Lancet. *Global Burden of Disease*. 2019. [www.thelancet.com/gbd](http://www.thelancet.com/gbd) (accessed: 28.08.2019).
2. Thomson Reuters. *The world's most influential scientific minds 2015*. 2015. <http://stateofinnovation.com/worlds-most-influential-scientific-minds-report-2015> (accessed: 11.03.2017).
3. British Medical Journal. *Europe is embracing the burden of disease approach*. 2016. <http://blogs.bmj.com/bmj/2016/10/04/claudia-stein-europe-is-embracing-the-burden-of-disease-approach/> (accessed: 28.08.2019).
4. Steel N, Ford JA, Newton JN, Davis ACJ, Vos T, Naghavi M, et al. Changes in health in the countries of the UK and 150 English Local Authority areas 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet* 2018; 392: 1647-61.
5. Newton JN, Briggs AD, Murray CJ, Dicker D, Foreman KJ, Wang H, et al. Changes in health in England, with analysis by English regions and areas of deprivation, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet* 2015; 386: 2257-74.
6. Norwegian Institute of Public Health. *Centre for Disease Burden*. 2019. [www.fhi.no/en/more/research-centres/senter-for-sykdomsbyrde/centre-for-burden-of-disease/](http://www.fhi.no/en/more/research-centres/senter-for-sykdomsbyrde/centre-for-burden-of-disease/) (accessed: 28.08.2019).
7. National Institutes of Health (NIH), US National Library of Medicine (NLM), ClinicalTrials.gov. *Swiss Diabetes Registry - SwissDiab Study (SwissDiab)*. 2019. <https://clinicaltrials.gov/ct2/show/NCT01179815> (accessed: 25.09.2019).
8. Institut für Hausarztmedizin der Universität Zürich (IHAMZ). *Das FIRE-Projekt*. 2019. <https://www.hausarztmedizin.uzh.ch/de/fire2.html> (accessed: 24.09.2019).
9. infofac - eMagazin der Ofac-Gruppe. *Siscare-DT2 hat die Zielvorgabe des BAG erreicht*. 2019. <http://www.infofac.net/de/siscare-t2d-hat-die-zielvorgabe-bag-erreicht/> (accessed: 24.09.2019).
10. HBCS Switzerland. *Health Behaviour in School-aged Children - A World Health Organization Collaborative Cross-national Study*. 2019. [www.hbcs.ch](http://www.hbcs.ch) (accessed: 24.09.2019).
11. National Institutes of Health (NIH), US National Library of Medicine (NLM). *PubMed*. 2019. [www.ncbi.nlm.nih.gov/pubmed](http://www.ncbi.nlm.nih.gov/pubmed) (accessed: 26.09.2019).
12. Berufsverband der Schweizer Ärztinnen und Ärzte (FMH). *Guidelines*. 2019. <https://www.fmh.ch/themen/qualitaet-saqm/guidelines.cfm> (accessed: 26.09.2019).
13. Schweizerischen Gesellschaft für Endokrinologie und Diabetologie (SGED). *Schweizerischen Gesellschaft für Endokrinologie und Diabetologie (SGED)*. 2019. [www.sgedssed.ch](http://www.sgedssed.ch) (accessed: 26.09.2019).
14. Programme Cantonal Diabète Vaud. *Recommendations pour la pratique clinique*. 2019. [www.recodiab.ch](http://www.recodiab.ch) (accessed: 26.09.2019).
15. QualiCCare. *QualiCCare - zur Verbesserung der Qualität in der Behandlung chronischer Krankheiten in der Schweiz*. 2019. <http://qualiccare.ch/> (accessed: 26.09.2019).
16. Vaud PCD. *Recommendation pour la Pratique Clinique (RPC) Multimorbidité*. 2019. <http://www.recodiab.ch> (accessed: 30.08.2019).
17. QualiCCare. *Multimorbide Patienten - Anwendung eine Praxisleitfadens zur Optimierung der Behandlungsqualität von Patienten mit mehreren chronischen nichtübertragbaren Krankheiten*. 2019. <http://qualiccare.ch/multimorbide-patienten> (accessed: 30.08.2019).
18. Schussele Filliettaz S, Berchtold P, Kohler D, Peytremann-Bridevaux I. Integrated care in Switzerland: Results from the first nationwide survey. *Health Policy* 2018; 122: 568-76.
19. Schussele Filliettaz S, Kohler D, Berchtold P, Peytremann-Bridevaux I. *Soins intégrés en Suisse. Résultats de la 1er enquête (2015-2016)*. Neuchâtel: OBSAN; 2017.

**Appendix 1: Workshop agenda**

<b>Time</b>	<b>Topic</b>	<b>Structure</b>
14:00-14:10	Welcome	Juerg Utzinger & Nicole Probst-Hensch
14:10-14:30	Introduction of participants	Plenum
14:30-15:00	Presentation of the project	Input presentation 1, Thomas Fürst
15:00-15:15	Immediate Q/A, reactions, discussion	Plenum, Moderation Thomas Fürst
15:15-15:30	Feedback/further completion stakeholder database	Plenum, Moderation Thomas Fürst
15:30-15:45	Feedback/further completion guidelines database	Plenum, Moderation Thomas Fürst
15:45-16:00	Feedback/further completion quantitative data database	Plenum, Moderation Thomas Fürst
16:00-16:30	Break	Break with refreshments
16:30-16:45	Integrated and patient-centered diabetes care	Input presentation 2, Thomas Fürst
16:45-17:00	Integrated and patient-centered diabetes care: criteria and characteristics?	Plenum, Co-Moderation Carlo de Pietro & Thomas Fürst
17:00-17:15	Integrated and patient-centered diabetes care: first list of providers and services known to participants	Plenum, Co-Moderation Carlo de Pietro & Thomas Fürst
17:15-17:30	Integrated and patient-centered diabetes care: approach to identifying additional providers and services after the workshop	Plenum, Co-Moderation Carlo de Pietro & Thomas Fürst
17:30-17:45	Input for a broader stakeholder consultation	Plenum, Moderation Thomas Fürst
17:45-17:50	Relevance of work on diabetes disease burden and patterns of care for him as GP, public health expert and representative of FMH	Plenum, Moderation Carlos Quinto
17:50-17:55	Relevance of work on diabetes disease burden and patterns of care for OBSAN	Plenum, Moderation Monika Diebold
17:55-18:00	Conclusion, thanks and farewell/closure	Plenum, Moderation Monika Diebold & Nicole Probst-Hensch

**Appendix 2: Workshop participants**

(in alphabetic order)

<b>Name</b>	<b>Relevant affiliation(s) and mandate(s)</b>	<b>Stakeholder classification</b>
Czock Astrid	<ul style="list-style-type: none"> <li>• QualiCCare</li> <li>• Schweizerische Gesellschaft für Endokrinologie und Diabetologie (SGED/SSED)</li> </ul>	<ul style="list-style-type: none"> <li>• Academia/Expert</li> <li>• Healthcare: Specialist doctors</li> </ul>
De Pietro Carlo	<ul style="list-style-type: none"> <li>• Dipartimento economia aziendale, sanità e sociale, Scuola Universitaria Professionale della Svizzera Italiana (SUPSI)</li> </ul>	<ul style="list-style-type: none"> <li>• Academia/Expert</li> </ul>
Diebold Monika	<ul style="list-style-type: none"> <li>• Swiss Health Observatory (OBSAN)</li> </ul>	<ul style="list-style-type: none"> <li>• Administration</li> </ul>
Fankhauser Pia	<ul style="list-style-type: none"> <li>• Independent Physiotherapist</li> <li>• Physioswiss</li> <li>• Plattform Interprofessionalität</li> </ul>	<ul style="list-style-type: none"> <li>• Healthcare: Physiotherapists</li> <li>• Academia/Expert</li> </ul>
Fischer-Taeschler Doris	<ul style="list-style-type: none"> <li>• Schweizerische Diabetes Stiftung (SDS)</li> <li>• Schweizerische Gesundheitsligenkonferenz (GELIKO)</li> <li>• Schweizerische Gesellschaft für Endokrinologie und Diabetologie (SGED/SSED)</li> <li>• Schweizerischen Gesellschaft für Pädiatrische Endokrinologie und Diabetologie (SGPED/SSEDP)</li> <li>• DIAfit</li> </ul>	<ul style="list-style-type: none"> <li>• Patients</li> <li>• Healthcare: Counselling &amp; Representation</li> <li>• Healthcare: Specialist doctors</li> </ul>
Fürst Thomas	<ul style="list-style-type: none"> <li>• Department Epidemiology and Public Health, Swiss TPH</li> </ul>	<ul style="list-style-type: none"> <li>• Academia/Expert</li> </ul>
Gabutti Luca	<ul style="list-style-type: none"> <li>• Internal Medicine, Ente Ospedaliero Cantonale (EOC)</li> <li>• Facoltà di Scienze Biomediche, Università della Svizzera Italiana (USI)</li> </ul>	<ul style="list-style-type: none"> <li>• Healthcare: Hospitals</li> <li>• Healthcare: Specialist doctors</li> <li>• Academia/Expert</li> </ul>
Güntert Bernhard	<ul style="list-style-type: none"> <li>• Curafutura</li> </ul>	<ul style="list-style-type: none"> <li>• Health Insurance</li> </ul>
Hagon-Traub Isabelle	<ul style="list-style-type: none"> <li>• Médecin Responsable Pôle Diabétologie, Ensemble Hospitalier de la Côte</li> <li>• Directrice Programme Diabète Canton Vaud</li> <li>• Vorstand diabetesschweiz</li> </ul>	<ul style="list-style-type: none"> <li>• Healthcare: Specialist doctors</li> <li>• Healthcare: Counselling &amp; Representation</li> <li>• Patients</li> </ul>

Name	Relevant affiliation(s) and mandate(s)	Stakeholder classification
Huber Claudia	<ul style="list-style-type: none"> <li>• Unité de Recherche en Interventions Infirmières complexes, Haute Ecole de Sante Fribourg</li> <li>• Co-Präsidentin Schweizerische Interessengruppe für Diabetesfachberatung (SIDB) des Schweizer Berufsverband der Pflegefachfrauen und Pflegefachmänner (SBK/ASI)</li> </ul>	<ul style="list-style-type: none"> <li>• Academia/Expert</li> <li>• Healthcare: Nursing</li> <li>• Healthcare: Counselling &amp; Representation</li> </ul>
Kaiser-Pfarrmann Eva	<ul style="list-style-type: none"> <li>• Independent GP</li> <li>• Haus- und Kinderärzte Schweiz (mfe)</li> </ul>	<ul style="list-style-type: none"> <li>• Healthcare: GP</li> </ul>
Krummenacher Isabelle	<ul style="list-style-type: none"> <li>• Schweizerischer Apotheker Verband (pharmaSuisse)</li> </ul>	<ul style="list-style-type: none"> <li>• Healthcare: Pharmacies</li> </ul>
Kündig Martin	<ul style="list-style-type: none"> <li>• Optometrist and manager Iseli Optik Basel</li> <li>• Schweizerische Berufsverband für Augenoptik und Optometrie (SBAO)</li> </ul>	<ul style="list-style-type: none"> <li>• Healthcare: optometrists/optician</li> </ul>
Leimgruber Christine	<ul style="list-style-type: none"> <li>• Diabetes Schweiz</li> </ul>	<ul style="list-style-type: none"> <li>• Healthcare: Counselling &amp; Representation</li> <li>• Patients</li> </ul>
Lucchini Barbara	<ul style="list-style-type: none"> <li>• Capo Servizio di Endocrinologia e Diabetologia, Ente Ospedaliero Cantonale (EOC)</li> </ul>	<ul style="list-style-type: none"> <li>• Healthcare: Hospitals</li> <li>• Healthcare: Specialist doctors</li> </ul>
Müller Beatrice	<ul style="list-style-type: none"> <li>• Klinik und Poliklinik für Innere Medizin, Universitätsspital Zürich</li> <li>• Schweizerische Gesellschaft für Allgemeine Innere Medizin (SGAIM)</li> </ul>	<ul style="list-style-type: none"> <li>• Healthcare: Hospitals</li> <li>• Healthcare: Specialist doctors</li> </ul>
Müller Nina C.	<ul style="list-style-type: none"> <li>• Augenklinik, Universitätsspital Basel</li> <li>• Schweizerische Berufsverband für Augenoptik und Optometrie (SBAO)</li> </ul>	<ul style="list-style-type: none"> <li>• Healthcare: optometrists/optician</li> <li>• Healthcare: Hospitals</li> </ul>

Name	Relevant affiliation(s) and mandate(s)	Stakeholder classification
Peytremann-Bridevaux Isabelle	<ul style="list-style-type: none"> <li>• Institut Universitaire de Médecine Sociale et Préventive (IUMSP), Université de Lausanne</li> <li>• Centre Hospitalier Universitaire Vaudois (CHUV)</li> </ul>	<ul style="list-style-type: none"> <li>• Academia/Expert</li> <li>• Healthcare: Specialist doctors</li> </ul>
Prandi Cesarina	<ul style="list-style-type: none"> <li>• Dipartimento economia aziendale, sanità e sociale (Focus Nursing), Scuola Universitaria Professionale della Svizzera Italiana (SUPSI)</li> </ul>	<ul style="list-style-type: none"> <li>• Academia/Expert</li> <li>• Healthcare: Nursing</li> </ul>
Probst-Hensch Nicole	<ul style="list-style-type: none"> <li>• Department Epidemiology and Public Health, Swiss TPH</li> </ul>	<ul style="list-style-type: none"> <li>• Academia/Expert</li> </ul>
Quinto Carlos	<ul style="list-style-type: none"> <li>• Department Epidemiology and Public Health, Swiss TPH</li> <li>• Zentralvorstand FMH</li> <li>• Independent GP</li> </ul>	<ul style="list-style-type: none"> <li>• Academia/Expert</li> <li>• Healthcare: GP</li> </ul>
Rodella Sapia Mirjam	<ul style="list-style-type: none"> <li>• Servizio di Medicina Interna, Ente Ospedaliero Cantonale (EOC)</li> <li>• Independent GP</li> <li>• Fachrat Public Health Schweiz</li> <li>• Lecturer Scuola Universitaria Professionale della Svizzera Italiana (SUPSI)</li> </ul>	<ul style="list-style-type: none"> <li>• Healthcare: Hospitals</li> <li>• Healthcare: GP</li> <li>• Academia/Expert</li> </ul>
Schenk Marianne	<ul style="list-style-type: none"> <li>• Schweizerischer Verband Medizinischer Praxis-Fachpersonen (SVA)</li> <li>• OdA Berufsbildung Medizinische Praxisassistentin (Odamed)</li> </ul>	<ul style="list-style-type: none"> <li>• Healthcare: medical practice assistants and medical practice coordinators</li> </ul>
Wieser Simon	<ul style="list-style-type: none"> <li>• Winterthurer Institut für Gesundheitsökonomie (WIG), Zürcher Hochschule für Angewandte Wissenschaften (ZHAW)</li> </ul>	<ul style="list-style-type: none"> <li>• Academia/Expert</li> </ul>



Appendix 3: Slides presented during workshop

Swiss TPH  
 Swiss Tropical and Public Health Institute  
 Schweizerisches Tropen- und Public Health Institut  
 Institut Tropical et de Santé Publique Suisse  
 Associated Institute of the University of Basel

Thomas Fürst  
 Department Epidemiology and Public Health

Stakeholder Workshop  
**Diabetes Mellitus: Disease Burden and Patterns of Care in Switzerland**  
 26 August 2019  
 Swiss TPH


SSPH+ SWISS SCHOOL OF PUBLIC HEALTH  
 SUPSI  
 Schweizerisches Gesundheitsobservatorium  
 Observatoire suisse de la santé  
 Osservatorio svizzero della salute  
 Swiss Health Observatory

Welcome & Introduction myself

Swiss TPH

**WELCOME**

> MA Geography, Economics, Sociology (University of Basel)  
 > PhD Epidemiology (Swiss TPH)  
 > Honorary Research Associate, Imperial College London  
 > Senior Scientific Collaborator, Swiss TPH




> Scientific Council Member, Global Burden of Disease (GBD) Collaboration  
 > Steering Group Member, WHO European Health Information Initiative (WHO EURO EHII)  
 > Founding Member, Joint IHME/WHO European Burden of Disease Network (EBoDN)  
 > Management Committee, COST Action <burden-eu>

26 August 2019 Workshop Diabetes 2

Welcome & Introduction myself

Swiss TPH

Burden of disease (BoD) background...



> Workshop participation of a large, divers, highly qualified group...  
 > Presentation of work in progress and some ideas...  
 > Wonderful opportunity – slightly nervous...  
 > BEAR WITH ME!

26 August 2019 Workshop Diabetes 3

This Workshop

Swiss TPH

> Excellent moment for a workshop!  
 > Receive input on first outputs  
 > Receive input on potential way(s) forward/ideas/"visions"  
 > Very positive feedback on workshop invitations – despite relatively short notice and during holiday season  
 > In the end 86 contacts and only from 9 no reaction at all  
 > Many who could not attend provided already additional input and emphasized their interest also in future involvement (outputs, other meetings, etc.)  
 > Slightly overwhelmed by reaction and also workshop attendance → active, spontaneous input from participants also on workshop structure most welcome – we have to be and are flexible!  
 > Topics of the project broad – backgrounds of workshop participants also diverse and interdisciplinary → bodes well!

26 August 2019 Workshop Diabetes 4

This Workshop

Swiss TPH

Time	Topic	Structure
14:00-14:10	Welcome	Juerg Utzinger & Nicole Probst-Hensch
14:10-14:30	Introduction of participants	Plenum
14:30-15:00	Presentation of the project	Input presentation 1, Thomas Fürst
15:00-15:15	Immediate Q/A, reactions, discussion	Plenum, Mod. Thomas Fürst
15:15-15:30	Feedback/further completion stakeholder database	Plenum, Mod. Thomas Fürst
15:30-15:45	Feedback/further completion guidelines database	Plenum, Mod. Thomas Fürst
15:45-16:00	Feedback/further completion quant. data database	Plenum, Mod. Thomas Fürst
16:00-16:30	Break	Break with refreshments
16:30-16:45	Integrated, patient-centered diabetes care (IPCDC)	Input presentation 2, Thomas Fürst
16:45-17:00	IPDC: criteria and characteristics?	Plenum, Co-Mod. Carlo de Pietro & Thomas Fürst
17:00-17:15	IPDC: first list of providers and services known to participants	Plenum, Co-Mod. Carlo de Pietro & Thomas Fürst
17:15-17:30	IPDC: approach to identifying additional providers and services after the workshop	Plenum, Co-Mod. Carlo de Pietro & Thomas Fürst
17:30-17:45	Input for a broader stakeholder consultation	Plenum, Moderation Thomas Fürst
17:45-17:50	Relevance of work for him as GP, public health expert and representative of FMH	Plenum, Moderation Carlos Quinto
17:50-17:55	Relevance of work for OBSAN	Plenum, Moderation Monika Diebold
17:55-18:00	Conclusion, thanks and farewell/closure	Plenum, Mod. Monika Diebold & Nicole Probst-Hensch

26 August 2019 Workshop Diabetes 5

The project

Swiss TPH



**OBSAN mandate: "Diabetes mellitus: Disease Burden and Patterns of Care in Switzerland"**

Financing workshop to explore "Burden of Disease Studies in Switzerland: Opportunities and Challenges" within its seed money programme "Foster Interuniversity Initiatives and Collaborations"

Partners in the SSPH+ workshop (and hopefully beyond...) (Carlo de Pietro, Luca Crivelli)

Partners in the OBSAN mandate and the SSPH+ workshop (and hopefully beyond...) (Simon Wieser, Julia Dratva)

26 August 2019 Workshop Diabetes 6



**The project** Swiss TPH 


**“Be clear about ‘stated’ and ‘latent’ objective”**

**Jan P. Vandenbroucke**



Stated/explicit objective of the research:	Latent/implicit objective in the research:
1) Diabetes mellitus (DM): disease burden in Switzerland 2) Diabetes mellitus (DM): patterns of care in Switzerland	3) Start stakeholder dialogue with (potential) partners in the fields of diabetes, burden and healthcare research in Switzerland 4) Explore opportunities and challenges that arise from burden of disease assessments in Switzerland – content-wise and personally
Main theme	Workshop contributing

26 August 2019
Workshop Diabetes
7

**The project** Swiss TPH 

**Introduction burden of disease**


- Who has heard of/knows what a (global) burden of disease study is?
- Who has heard of/knows what disability-adjusted life years (DALYs) are?

«Burden» and «Summary measures of population health (SMPH)» of a disease, injury, or risk factor often used in a wider, intuitive, but also unprecise way – for instance, often just as a synonym for prevalence, incidence, clinical manifestations, mortality, socioeconomic consequences, etc.

In a narrower, stricter and preciser sense, the (health) «burden» of a disease, injury, or risk factor is assessed by using «summary measures of population health (SMPH)» as measurement methods.

Summary measures of population health are measures that combine information on mortality and non-fatal health outcomes to represent the health of a particular population as a single number. (Field & Gold 1998)

26 August 2019
Workshop Diabetes
8

**The project** Swiss TPH 

**Introduction burden of disease**


➢ What should be considered in a «summary measure of population health»?

1. Progression of a health condition/causally attributable sequelae
2. Incidence of sequelae
3. Prevalence of sequelae
4. «Morbidity» / «Severity» of sequelae
5. Duration of sequelae
6. Remission/Cure rate from sequelae
7. Case fatality/Mortality of sequelae
- ~~8. Health-service attendance due to sequelae~~
- ~~9. Socioeconomic status of person with sequelae~~
- ~~10. Equity / «Fairness» considerations~~
- ~~11. Other (also non-health) factors~~

Briefly (2-3 min. max) discuss pros and cons with your neighbour(s) of each indicator on its own and/or in combination(s)


Basic descriptive epidemiology key indicators!!!

26 August 2019
Workshop Diabetes
9


**The project** Swiss TPH 

**Introduction burden of disease**

- Traditionally, often mortality indicators in the form of cause-specific case fatality rates, life tables and life expectancies used
- Still today, a good «natural» starting point as basis to understand the construction of most further refined «summary measure of population health»
- (Cause-specific) mortality tells you a lot about the health of a population... but it does not tell you the full story!
- Some of the most prevalent and expensive conditions for a health system – particularly in high-income countries – are chronic and do not (anymore) lead to much premature death
- Probably the two most often used «summary measure of population health» at the moment
  - Quality-adjusted life years (QALYs)
  - Disability-adjusted life years (DALYs)



26 August 2019
Workshop Diabetes
10

**The project** Swiss TPH 

**Introduction burden of disease**

➢ DALYs time-based measure of health loss and calculated – for a certain population, year, and sequela – as follows:

- DALYs = YLL + YLD
- YLL = Years of life lost (due to premature death) = N \* L
- YLD = Years lived with disability = P \* DW (= I \* D \* DW)


- N = Number of deaths
- L = (Standard) Life expectancy at age of death
- P = Prevalence
- DW = Disability weight (scale from 0=full health to 1=death; analogy disability insurance IV/AI)

(• I = Incidence )  
(• D = Duration )  
(• R = Remission/Cure rate)

Qualitative model for progression / causally attributable sequelae

Quantitative data

26 August 2019
Workshop Diabetes
11

**The project** Swiss TPH 

**Introduction burden of disease**

	OBSAN / BFS	IDF	GBD
Reference year	2017	2017	2017
Reference population	Residents, ≥15 y. o.	Residents, 20-79 y. o.	All residents
DM prevalence "confirmed", in % of total pop.	4.6	4.8	10.5
DM prevalence "undiagnosed", in % of total pop.	?	2.6	?
DM prevalence "total", in % of total pop.	4.6	7.4	10.5
Total number of deaths due to DM	1,274	1,800	1,123
Total DALYs lost due to DM	?	?	74,780
Cause-specific ranking DM* ("if all overall health losses measured in DALYs)	?	?	4
Additional annual health expenditure per diabetic** ("people with diabetes have average two times higher healthcare expenditure than people without diabetes)	?	CHF 5,000-6,000	?

➢ Short extrapolation:  
National difference in prevalence of 1% ≈ 85,000 people;  
→ national difference in annual health expenditure: CHF 425-510 Mio.

26 August 2019
Workshop Diabetes
12

**The project**  
Introduction burden of disease

Swiss TPH

➤ Swiss data the "gold standard"  
➤ E.g. GBD results:

Results for Nonfatal Health Outcomes, Switzerland, Diabetes mellitus

**Total Results**

Note that total results refers to the number of distinct input sources listed here. Your download may have many more rows.

**Alcohol consumption and incidence of type 2 diabetes. Results from the CoLaus study**  
Marques-Vidal P, Vollenweider P, Waehler G. Alcohol consumption and incidence of type 2 diabetes. Results from the CoLaus study. *Nutr Metab Cardiovasc Dis.* 2013; 23(1): 79-84.

**Estimating the risk of developing type 2 diabetes: a comparison of several risk scores: the Cohort de Lausanne study**  
Schmid R, Vollenweider P, Waehler G, Marques-Vidal P. Estimating the risk of developing type 2 diabetes: a comparison of several risk scores: the Cohort de Lausanne study. *Diabetes Care.* 2011; 34(9): 1952-6.

**Genetic and phenotypic determinants of blood pressure and other cardiovascular risk factors (GAPP)**  
Conen D, Schoen T, Aeschbacher S, Park G, Freyher W, Bach M, Bach L. Genetic and phenotypic determinants of blood pressure and other cardiovascular risk factors (GAPP). *Swiss Med Wkly.* 2012; 142: w23728.

**Objective sleep structure and cardiovascular risk factors in the general population: the Hypnoslaus Study**  
Habe-Rubio J, Marques-Vidal P, Andres D, Tobback N, Preisig M, Vollenweider P, Waehler G, Luca G, Taff M, Herzer R. Objective sleep structure and cardiovascular risk factors in the general population: the Hypnoslaus Study. 2015; 38(2): 391-400.

**Prevalence, awareness and treatment of type 2 diabetes mellitus in Switzerland: the CoLaus study**  
Keller A, Vollenweider P, Waehler G, Marques-Vidal P. Prevalence, awareness and treatment of type 2 diabetes mellitus in Switzerland: the CoLaus study. *Diabet Med.* 2012; 29(2): 190-7.

**Prevalence, treatment and control of dyslipidaemia in Switzerland: still a long way to go**  
Firmann M, Marques-Vidal P, Paccaud F, Moser V, Rodondi N, Waehler G, Vollenweider P. Prevalence, treatment and control of dyslipidaemia in Switzerland: still a long way to go. *Int J Cardiovasc Prev Rehabil.* 2010; 17(8): 462-7.

WHO Mortality Database

26 August 2019 Workshop Diabetes 13

**The project**  
Introduction burden of disease

Swiss TPH

Pro 1: Systematic approach to look at basic descriptive epidemiology key indicators: What do we know (incl. (inter)nat. comparison)?

(inter)nat. comparison → feedback

➤ Easily comparable quantitative estimates of health loss – considering mortality and morbidity – across causes, populations and population groups (e.g. by age and/or sex), locations and time

➤ "Top-down"/"remote sensing"; assembling bits and pieces to provide an as high-resolution picture of the overall population health/health loss as possible – no need to necessarily have data linked at individual level, therefore also less data protection issues → highly relevant in "fragmented" Swiss public health landscape

➤ Current state of knowledge and knowledge gaps (inexistence or inaccessibility of data)

26 August 2019 Workshop Diabetes 14

**The project**  
Introduction burden of disease

Swiss TPH

Pro 2: Some countries also in Western Europe (e.g. England, Scotland, Norway, Germany) working and using BoD approach and generally report positive experiences

Mind the gap: Seventy years after the NHS was founded, a new survey shows a shocking health divide between rich and poor  
*independent.co.uk*, 15 Sep 2015. Keyword: PHE. Journalist: Not Credited

More deaths linked to bad diet than cigs  
*thesun.co.uk*, 15 Sep 2015. Keyword: Public Health England. Journalist: Not Credited

LIFE EXPECTANCY RISING BUT BAD DIET AND SMOKING STILL 'BIG RISKS TO HEALTH'  
*PA News Wire*, 15 Sep 2015. Keyword: PHE. Journalist: Helen William

Where in England Do People Live The Longest?  
*news.sky.com*, 15 Sep 2015. Keyword: PHE. Journalist: Not Credited

Life expectancy rose from 75.6 years to 81.3 years between 1990 and 2013, says Public Health England.  
*dailymail.co.uk*, 15 Sep 2015. Keyword: PHE. Journalist: Sam Matthew

**"Burden of disease studies seem to provide a new packaging for communicating old and new public health findings to the general public"**

**John Newton**  
(Director of Health Improvement, Public Health England)

26 August 2019 Workshop Diabetes 15

**The project**  
Introduction burden of disease

Swiss TPH

Pro 3 / Con 1: Start the discussion, based on a clear methodology, but...

"Without data you're just another person with an opinion."

- W. Edwards Deming, Data Scientist

Con 2: (Over-)Simplification

Con 3: DALYs only on one condition not useful... (However, start somewhere and continuous further refinements...?)

26 August 2019 Workshop Diabetes 16

**The project**  
Introduction burden of disease

Swiss TPH

Time	Topic	Structure
14:00-14:10	Welcome	Juerg Utzinger & Nicole Probst-Hensch
14:10-14:30	Introduction of participants	Plenum
14:30-15:00	Presentation of the project	Input presentation 1, Thomas Fürst
15:00-15:15	Immediate Q/A, reactions, discussion	Plenum, Mod. Thomas Fürst
15:15-15:30	Feedback/further completion stakeholder database	Plenum, Mod. Thomas Fürst
15:30-15:45	Feedback/further completion guidelines database	Plenum, Mod. Thomas Fürst
15:45-16:00	Feedback/further completion quant. data database	Plenum, Mod. Thomas Fürst
16:00-16:30	Break	Break with refreshments
16:30-16:45	Integrated, patient-centered diabetes care (IPCCD)	Input presentation 2, Thomas Fürst
16:45-17:00	IPCCD: criteria and characteristics?	Plenum, Co-Mod. Carlo de Pietro & Thomas Fürst
17:00-17:15	IPCCD: first list of providers and services known to participants	Plenum, Co-Mod. Carlo de Pietro & Thomas Fürst
17:15-17:30	IPCCD: approach to identifying additional providers and services after the workshop	Plenum, Co-Mod. Carlo de Pietro & Thomas Fürst
17:30-17:45	Input for a broader stakeholder consultation	Plenum, Moderation Thomas Fürst
17:45-17:50	Relevance of work for him as GP, public health expert and representative of FMH	Plenum, Moderation Carlos Quinto
17:50-17:55	Relevance of work for OBSAN	Plenum, Moderation Monika Diebold
17:55-18:00	Conclusion, thanks and farewell/closure	Plenum, Mod. Monika Diebold & Nicole Probst-Hensch

26 August 2019 Workshop Diabetes 17

**The project**  
DM patterns of care in Switzerland

Swiss TPH

➤ Patterns of care ↔ disease progression ↔ population health ↔ BoD assessments

➤ Substantial inaccuracies in international efforts (e.g. GBD study) recognized in some countries (e.g. Scotland)

➤ Patterns of care relevant per se, of course!






26 August 2019 Workshop Diabetes 18

### The project DM patterns of care in Switzerland

Swiss TPH

Time	Topic	Structure
14:00-14:10	Welcome	Juerg Utzinger & Nicole Probst-Hensch
14:10-14:30	Introduction of participants	Plenum
14:30-15:00	Presentation of the project	Input presentation 1, Thomas Fürst
15:00-15:15	Immediate Q/A, reactions, discussion	Plenum, Mod. Thomas Fürst
15:15-15:30	Feedback/further completion stakeholder database	Plenum, Mod. Thomas Fürst
15:30-15:45	Feedback/further completion guidelines database	Plenum, Mod. Thomas Fürst
15:45-16:00	Feedback/further completion quant. data database	Plenum, Mod. Thomas Fürst
16:00-16:30	Break	Break with refreshments
16:30-16:45	Integrated, patient-centered diabetes care (IPCCD)	Input presentation 2, Thomas Fürst
16:45-17:00	IPCCD: criteria and characteristics?	Plenum, Co-Mod. Carlo de Pietro & Thomas Fürst
17:00-17:15	IPCCD: first list of providers and services known to participants	Plenum, Co-Mod. Carlo de Pietro & Thomas Fürst
17:15-17:30	IPCCD: approach to identifying additional providers and services after the workshop	Plenum, Co-Mod. Carlo de Pietro & Thomas Fürst
17:30-17:45	Input for a broader stakeholder consultation	Plenum, Moderation Thomas Fürst
17:45-17:50	Relevance of work for him as GP, public health expert and representative of FMH	Plenum, Moderation Carlos Quinto
17:50-17:55	Relevance of work for OBSAN	Plenum, Moderation Monika Diebold
17:55-18:00	Conclusion, thanks and farewell/closure	Plenum, Mod. Monika Diebold & Nicole Probst-Hensch

26 August 2019 Workshop Diabetes 19



### The project DM patterns of care in Switzerland


Swiss TPH 

**Healthcare database**

- > **Guidelines:**
  - > FMH online platform ([www.guidelines.fmh.ch](http://www.guidelines.fmh.ch))
- > **Healthcare providers:**
  - > Combination of health professions from
    - Schweizerisches Dienstleistungszentrum Berufsbildung/Centre Suisse de Services Formation Professionnelle (EDK; [www.berufsberatung.ch](http://www.berufsberatung.ch))
    - FMH Facharzttitel und Schwerpunkte/FMH Titres de Spécialiste et Formations approfondies (FMH; [www.fmh.ch/siwf/siwf/weiterbildung/facharzttitel-und-schwerpunkte.cfm](http://www.fmh.ch/siwf/siwf/weiterbildung/facharzttitel-und-schwerpunkte.cfm))
    - Oggler (2015) Gesundheitswesen Schweiz 2015-2017. Hogrefe Verlag, Bern.
    - BFS (2017) Schweizerische Berufsnomenklatur 2000 / Nomenclature Suisse des Professions 2000
  - > Relevance of health professions in diabetes care based on disease model
  - > Based on relevant health professions identified relevant institutions and organizations

26 August 2019 Workshop Diabetes 25

### The project DM patterns of care in Switzerland

Swiss TPH 

**Healthcare database**

- > **Healthcare providers**
  - Briefly switch to XLS

**Stakeholder Database**

- > Healthcare providers: professions, institutions, organizations
- > Patients
- > Health Insurance
- > Administration
- > Academia / Experts

(Limited) snowball sampling

↓

Workshop participants, i.e. YOU

26 August 2019 Workshop Diabetes 26

### The project DM patterns of care in Switzerland


Swiss TPH 

- > Despite good match between disease models and healthcare providers, not happy – do not capture “patterns of care” very well...
- > No clear “...overview of diabetes healthcare providers and services to inform health professionals, politicians, patients and other partners...”
- > Not very systematic; separate listings/databases, but no clear interlinkage




26 August 2019 Workshop Diabetes 27

### The project DM patterns of care in Switzerland


Swiss TPH 

> Structure/Conceptualization




26 August 2019 Workshop Diabetes 28

### The project DM patterns of care in Switzerland


Swiss TPH 

> Structure/Conceptualization




26 August 2019 Workshop Diabetes 29

### The project DM patterns of care in Switzerland

Swiss TPH 

> Structure/Conceptualization



**First aid 6W scheme:**  
 Wann? – When?  
 Wer? – Who?  
 Was? – What?  
 Wo? – Where?  
 Wieviel? – How many?  
 Weiteres? – Additional?

26 August 2019 Workshop Diabetes 30

**The project**  
DM patterns of care in Switzerland

Swiss TPH

➤ Structure/Conceptualization

**First aid 6W scheme:**  
Wann? – When?  
Wer? – Who?  
Was? – What?  
Wo? – Where?  
Wieviel? – How many?  
Weiteres? – Additional?

26 August 2019 Workshop Diabetes 31

**The project**  
DM patterns of care in Switzerland

Swiss TPH

➤ Structure/Conceptualization

**First aid 6W scheme:**  
Wann? – When?  
Wer? – Who?  
Was? – What?  
Wo? – Where?  
Wieviel? – How many?  
Weiteres? – Additional?

26 August 2019 Workshop Diabetes 32

**The project**  
DM patterns of care in Switzerland

Swiss TPH

➤ Structure/Conceptualization

**First aid 6W scheme:**  
Wann? – When?  
Wer? – Who?  
Was? – What?  
Wo? – Where?  
Wieviel? – How many?  
Weiteres? – Additional?

26 August 2019 Workshop Diabetes 33

**The project**  
DM patterns of care in Switzerland

Swiss TPH

➤ Structure/Conceptualization

**First aid 6W scheme:**  
Wann? – When?  
Wer? – Who?  
Was? – What?  
Wo? – Where?  
Wieviel? – How many?  
Weiteres? – Additional?

26 August 2019 Workshop Diabetes 34

**The project**  
DM patterns of care in Switzerland

Swiss TPH

➤ Structure/Conceptualization

**First aid 6W scheme:**  
Wann? – When?  
Wer? – Who?  
Was? – What?  
Wo? – Where?  
Wieviel? – How many?  
Weiteres? – Additional?

26 August 2019 Workshop Diabetes 35

**The project**  
DM patterns of care in Switzerland


Swiss TPH

➤ Structure/Conceptualization

**First aid 6W scheme:**  
Wann? – When?  
Wer? – Who?  
Was? – What?  
Wo? – Where?  
Wieviel? – How many?  
Weiteres? – Additional?

26 August 2019 Workshop Diabetes 36

### The project DM patterns of care in Switzerland

Swiss TPH 

➤ **Structure/Conceptualization**

- More systematic
- Better validity (correctness and consistency of content)
- Better reliability (replicability)
- Interlinkages clearer
- Clearer "...overview of diabetes healthcare providers and services to inform health professionals, politicians, patients and other partners..." ?
- Look-up tool ?
- If conceptualization/definition of "integrated diabetes care" clearer (more on that later!):
  - Survey among institutions and respective entries/"labelling" in database – quality of care/"marketing" aspect ?
  - Transparency/Decision support for patients, payer, politicians... ?
- (Transferable... ?)

26 August 2019 Workshop Diabetes 37


### This Workshop

Swiss TPH 

Time	Topic	Structure
14:00-14:10	Welcome	Juerg Utzinger & Nicole Probst-Hensch
14:10-14:30	Introduction of participants	Plenum
14:30-15:00	Presentation of the project	Input presentation 1, Thomas Fürst
15:00-15:15	Immediate Q/A, reactions, discussion	Plenum, Mod. Thomas Fürst
15:15-15:30	Feedback/further completion stakeholder database	Plenum, Mod. Thomas Fürst
15:30-15:45	Feedback/further completion guidelines database	Plenum, Mod. Thomas Fürst
15:45-16:00	Feedback/further completion quant. data database	Plenum, Mod. Thomas Fürst
16:00-16:30	Break	Break with refreshments
16:30-16:45	Integrated, patient-centered diabetes care (IPDCI)	Input presentation 2, Thomas Fürst
16:45-17:00	IPDCI: criteria and characteristics?	Plenum, Co-Mod. Carlo de Pietro & Thomas Fürst
17:00-17:15	IPDCI: first list of providers and services known to participants	Plenum, Co-Mod. Carlo de Pietro & Thomas Fürst
17:15-17:30	IPDCI: approach to identifying additional providers and services after the workshop	Plenum, Co-Mod. Carlo de Pietro & Thomas Fürst
17:30-17:45	Input for a broader stakeholder consultation	Plenum, Moderation Thomas Fürst
17:45-17:50	Relevance of work for him as GP, public health expert and representative of FMH	Plenum, Moderation Carlos Quinto
17:50-17:55	Relevance of work for OBSAN	Plenum, Moderation Monika Diebold
17:55-18:00	Conclusion, thanks and farewell/closure	Plenum, Mod. Monika Diebold & Nicole Probst-Hensch

26 August 2019 Workshop Diabetes 38


### This Workshop

Swiss TPH 

Time	Topic	Structure
14:00-14:10	Welcome	Juerg Utzinger & Nicole Probst-Hensch
14:10-14:30	Introduction of participants	Plenum
14:30-15:00	Presentation of the project	Input presentation 1, Thomas Fürst
15:00-15:15	Immediate Q/A, reactions, discussion	Plenum, Mod. Thomas Fürst
15:15-15:30	Feedback/further completion stakeholder database	Plenum, Mod. Thomas Fürst
15:30-15:45	Feedback/further completion guidelines database	Plenum, Mod. Thomas Fürst
15:45-16:00	Feedback/further completion quant. data database	Plenum, Mod. Thomas Fürst
16:00-16:30	Break	Break with refreshments
16:30-16:45	Integrated, patient-centered diabetes care (IPDCI)	Input presentation 2, Thomas Fürst
16:45-17:00	IPDCI: criteria and characteristics?	Plenum, Co-Mod. Carlo de Pietro & Thomas Fürst
17:00-17:15	IPDCI: first list of providers and services known to participants	Plenum, Co-Mod. Carlo de Pietro & Thomas Fürst
17:15-17:30	IPDCI: approach to identifying additional providers and services after the workshop	Plenum, Co-Mod. Carlo de Pietro & Thomas Fürst
17:30-17:45	Input for a broader stakeholder consultation	Plenum, Moderation Thomas Fürst
17:45-17:50	Relevance of work for him as GP, public health expert and representative of FMH	Plenum, Moderation Carlos Quinto
17:50-17:55	Relevance of work for OBSAN	Plenum, Moderation Monika Diebold
17:55-18:00	Conclusion, thanks and farewell/closure	Plenum, Mod. Monika Diebold & Nicole Probst-Hensch

26 August 2019 Workshop Diabetes 39

### Stakeholder Database


Swiss TPH 

- 1) Any major stakeholder category missing?  
 A=Patients; B=Health Care Providers; C=Health Insurance; D=Administration; E=Academia/Experts
- 2) Classification (*high, medium, low*) of stakeholder relevance (*diabetes key expertise/activities/involvement -- also in light of our project*) ok?
- 3) Any specific stakeholder missing (obviously physiotherapy with physioswiss as stakeholder under B--practice)?
- 4) Other comments?

→ see XLS

26 August 2019 Workshop Diabetes 40

### Health Care Database

Swiss TPH 

**Healthcare database**

➤ **Healthcare providers:**


- 1) Identical to section B in stakeholder database!
- 2) Do lists of individuals in resp. health professions exist (optimally with exhaustive and mutually exclusive categorization)?  
 Accessible?  
 If not, what else could be used?
- 3) Do lists of resp. healthcare institutions exist (optimally with exhaustive and mutually exclusive categorization)?  
 Accessible?  
 If not, what else could be used?

→ for relevance, see the revised/proposed "Structure/Conceptualisation" (slides 28-38)

→ see XLS

26 August 2019 Workshop Diabetes 41

### Health Care Database

Swiss TPH 

**Healthcare database**

➤ **Guidelines:**

- 1) All guidelines from FMH online platform ([www.guidelines\\_fmh.ch](http://www.guidelines_fmh.ch)) – additional, publicly available guidelines – optimally also in a repository?
- 2) Is it true that ca. 1/3 are expired? Any new editions of the expired ones?
- 3) Has anyone access to Nr. 11 ("PizolCare: Patientenpfad Diabetes mellitus") and could share it with us?
- 4) Any idea/"feeling" about application relevance and utilization frequency/compliance with these publicly available guidelines?
- 5) Any idea/"feeling" about application relevance and utilization frequency/compliance with not publicly available guidelines, i.e. internal guidelines within GP networks, hospitals, etc. ?

→ see XLS


26 August 2019 Workshop Diabetes 42





**This Workshop** Swiss TPH 

Time	Topic	Structure
14:00-14:10	Welcome	Juerg Utzinger & Nicole Probst-Hensch
14:10-14:30	Introduction of participants	Plenum
14:30-15:00	Presentation of the project	Input presentation 1, Thomas Fürst
15:00-15:15	Immediate Q/A, reactions, discussion	Plenum, Mod. Thomas Fürst
15:15-15:30	Feedback/further completion stakeholder database	Plenum, Mod. Thomas Fürst
15:30-15:45	Feedback/further completion guidelines database	Plenum, Mod. Thomas Fürst
15:45-16:00	Feedback/further completion quant. data database	Plenum, Mod. Thomas Fürst
16:00-16:30	Break	Break with refreshments
16:30-16:45	Integrated, patient-centered diabetes care (IPDC)	Input presentation 2, Thomas Fürst
16:45-17:00	IPDC: criteria and characteristics?	Plenum, Co-Mod. Carlo de Pietro & Thomas Fürst
17:00-17:15	IPDC: first list of providers and services known to participants	Plenum, Co-Mod. Carlo de Pietro & Thomas Fürst
17:15-17:30	IPDC: approach to identifying additional providers and services after the workshop	Plenum, Co-Mod. Carlo de Pietro & Thomas Fürst
17:30-17:45	Input for a broader stakeholder consultation	Plenum, Moderation Thomas Fürst
17:45-17:50	Relevance of work for him as GP, public health expert and representative of FMH	Plenum, Moderation Carlos Quinto
17:50-17:55	Relevance of work for OBSAN	Plenum, Moderation Monika Diebold
17:55-18:00	Conclusion, thanks and farewell/closure	Plenum, Mod. Monika Diebold & Nicole Probst-Hensch


26 August 2019 Workshop Diabetes 49

**Reminder** Swiss TPH 

# BREAK





26 August 2019 Workshop Diabetes 50


**This Workshop** Swiss TPH 

Time	Topic	Structure
14:00-14:10	Welcome	Juerg Utzinger & Nicole Probst-Hensch
14:10-14:30	Introduction of participants	Plenum
14:30-15:00	Presentation of the project	Input presentation 1, Thomas Fürst
15:00-15:15	Immediate Q/A, reactions, discussion	Plenum, Mod. Thomas Fürst
15:15-15:30	Feedback/further completion stakeholder database	Plenum, Mod. Thomas Fürst
15:30-15:45	Feedback/further completion guidelines database	Plenum, Mod. Thomas Fürst
15:45-16:00	Feedback/further completion quant. data database	Plenum, Mod. Thomas Fürst
16:00-16:30	Break	Break with refreshments
16:30-16:45	Integrated, patient-centered diabetes care (IPDC)	Input presentation 2, Thomas Fürst
16:45-17:00	IPDC: criteria and characteristics?	Plenum, Co-Mod. Carlo de Pietro & Thomas Fürst
17:00-17:15	IPDC: first list of providers and services known to participants	Plenum, Co-Mod. Carlo de Pietro & Thomas Fürst
17:15-17:30	IPDC: approach to identifying additional providers and services after the workshop	Plenum, Co-Mod. Carlo de Pietro & Thomas Fürst
17:30-17:45	Input for a broader stakeholder consultation	Plenum, Moderation Thomas Fürst
17:45-17:50	Relevance of work for him as GP, public health expert and representative of FMH	Plenum, Moderation Carlos Quinto
17:50-17:55	Relevance of work for OBSAN	Plenum, Moderation Monika Diebold
17:55-18:00	Conclusion, thanks and farewell/closure	Plenum, Mod. Monika Diebold & Nicole Probst-Hensch


26 August 2019 Workshop Diabetes 51

**Integrated diabetes care** Swiss TPH 

- > Generally, no clear consensus and definition of “integrated care” exists thus far
- > “Integrated diabetes care” desirable...
  - > ...but what does it mean?
  - > ...relevant and operationalizable criteria/definition?
  - > ...how to capture thus defined, available integrated diabetes care initiatives?
  - > ...additional useful characteristics to well describe the identified integrated diabetes care initiatives?
- > Considered as good starting point: shared article on the first Swiss Survey on Integrated Care (SSIC), published in Health Policy last year
  - > Most happy to have the senior author of this article with us today, Prof. Peytremann-Bridevaux!




26 August 2019 Workshop Diabetes 52

**Integrated diabetes care** Swiss TPH 

- > According to the article, SSIC used to following inclusion criteria to define “integrated care initiatives”:
  - > Formalization (formal written agreement between organizations/ institutions)
  - > Integration at healthcare services level (at least 2; e.g. physician-led primary car, non-physician-led primary car, specialized medical outpatient service, home care, community services, etc.)
  - > Integration at healthcare professionals level (at least 2; e.g. specialist physician, GP, general nurse, specialist nurse, FaGE(assistant en soins et santé)/MPA(assistant médicales), nutritionist, pharmacist, optometrist, physiotherapist, etc.)
  - > Ongoing

26 August 2019 Workshop Diabetes 53

**Integrated diabetes care** Swiss TPH 

- > According to the article, SSIC used several exclusion criteria to define “integrated care initiatives”, probably most relevant for this work:
  - > “Provision of “usual care” (such as multidisciplinary diabetic teams, tumor boards, pain centers, wound centers, memory centers)”
- > Questions to Prof. Peytremann-Bridevaux – not to be lazy, but pragmatic:
  - > Due to the aforementioned exclusion criteria, one could probably not ‘simply’ draw a subset of the SSIC to obtain a good overview of “integrated diabetes care” initiatives – one would miss those who have already become “usual care”; correct?
  - > If one could ‘simply’ draw such a subset to obtain a good overview of “integrated diabetes care” initiatives, this would be a strong argument for adopting the exact same definition/criteria as in the SSIC...
- > Otherwise – as aforementioned and to all: What would be relevant and operationalizable criteria/definition for “Integrated diabetes care”?


26 August 2019 Workshop Diabetes 54





**Next steps**

- Digest
- Send workshop participants material
- Further stakeholder consultation – Incl. workshop participants again, if ok
- Final synthesis & (quant.) analysis & write up and share final material again with all participants



**Thank you**

- Ok, if we approach you also after the workshop with limited, targeted questions, if need be?
  - Would be most grateful – and one essential goal is to start and maintain stakeholder dialogue as...

**“Be close to patients and practitioners!”**

**Jan P. Vandenbroucke**



**THANK YOU !!!**

**This Workshop**

Time	Topic	Structure
14:00-14:10	Welcome	Juerg Utzinger & Nicole Probst-Hensch
14:10-14:30	Introduction of participants	Plenum
14:30-15:00	Presentation of the project	Input presentation 1, Thomas Fürst
15:00-15:15	Immediate Q/A, reactions, discussion	Plenum, Mod. Thomas Fürst
15:15-15:30	Feedback/further completion stakeholder database	Plenum, Mod. Thomas Fürst
15:30-15:45	Feedback/further completion guidelines database	Plenum, Mod. Thomas Fürst
15:45-16:00	Feedback/further completion quant. data database	Plenum, Mod. Thomas Fürst
16:00-16:30	Break	Break with refreshments
16:30-16:45	Integrated, patient-centered diabetes care (IPCDC)	Input presentation 2, Thomas Fürst
16:45-17:00	IPCDC: criteria and characteristics?	Plenum, Co-Mod. Carlo de Pietro & Thomas Fürst
17:00-17:15	IPCDC: first list of providers and services known to participants	Plenum, Co-Mod. Carlo de Pietro & Thomas Fürst
17:15-17:30	IPCDC: approach to identifying additional providers and services after the workshop	Plenum, Co-Mod. Carlo de Pietro & Thomas Fürst
17:30-17:45	Input for a broader stakeholder consultation	Plenum, Moderation Thomas Fürst
17:45-17:50	Relevance of work for him as GP, public health expert and representative of FMH	Plenum, Moderation Carlos Quinto
17:50-17:55	Relevance of work for OBSAN	Plenum, Moderation Monika Diebold
17:55-18:00	Conclusion, thanks and farewell/closure	Plenum, Mod. Monika Diebold & Nicole Probst-Hensch